Origio Limited
Registered name: ORIGIO LIMITED
Part of The Cooper Companies, Inc. groupOrigio Limited made £20.1m revenue and £499k profit in the year to 31 Oct 2025.
Origio Limited’s revenue grew 23% to £20.1m in the year to 31 Oct 2025, with £499k profit and 82 employees. The company is classified under “research and experimental development on biotechnology” and is based in Fareham; we hold 4 years of its filed accounts.
- Status
- Active
- Location
- Fareham, South East
- Age
- 30 yrs · since 1996
- Type
- Private Limited Company
Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently. From the filing: “Origio A/S”
Key figures
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 Oct 2021 | 31 Oct 2022 | 31 Oct 2024 | 31 Oct 2025 |
|---|---|---|---|---|
| Disclosure | Full P&L | Full P&L | Full P&L | Full P&L |
| Profit & loss | ||||
| Revenue (turnover) | £9.7m | £13.7m | £16.2m | £20.1m |
| Cost of sales | £3.6m | £4.6m | £4.8m | £8.1m |
| Gross profit | £6.1m | £9.1m | £11.4m | £11.9m |
| Profit before tax | £286k | −£272k | £493k | £655k |
| Profit after tax | £201k | −£127k | £370k | £499k |
| Profit (best available) | £201k | −£127k | £370k | £499k |
| Staff costs | £4.7m | £6.4m | £9.2m | £9.3m |
| Employees (average) | 48 | 62 | 81 | 82 |
| Ratios | ||||
| Profit margin | 2.1% | −0.9% | 2.3% | 2.5% |
| Gross margin | 62.8% | 66.4% | 70.3% | 59.4% |
| Revenue per employee | £202k | £221k | £201k | £245k |
| Profit per employee | £4.2k | −£2.1k | £4.6k | £6.1k |
| Growth (year on year) | ||||
| Revenue growth | — | ▲41.6% | — | ▲23.4% |
| Profit growth | — | ▼163.2% | — | ▲34.9% |
| Headcount growth | — | ▲29.2% | — | ▲1.2% |
| Balance sheet — indirect signals, not revenue | ||||
| Cash at bank | £1m | £843k | £1.2m | £1.7m |
| Net assets | £1.6m | £1.5m | £2.7m | £3.2m |
| Fixed assets | £972 | £816 | £197k | £188k |
| Current assets | £3.4m | £5m | £5.9m | £6.4m |
| Debtors | £2.2m | £3.9m | £4.4m | £4.5m |
| Source | Accounts · bulk data Oct 2023 | Accounts · bulk data Oct 2023 | FullAccounts · bulk data Jul 2026 | FullAccounts · bulk data Jul 2026 |
How the business works
- Profit margin
- 2.5%
- Profit ÷ revenue.
- Gross margin
- 59.4%
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- £245k
- Revenue ÷ average employees.
- Profit per employee
- £6.1k
- Profit ÷ average employees.
- Cash conversion
- —
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- 0.9%
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- —
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- 22.6%
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- ▲19%
- Now £3.2m
- Cash at bank
- ▲37%
- Now £1.7m
- Headcount
- ▲1%
- Now 82
- Deferred income
- —
- Now —
- Fixed assets
- ▼4%
- Now £188k
Group structure
Ownership chain
- The Cooper Companies, Inc. (registered outside the UK register)ultimate parent75–100%
- Coopersurgical Holdings Limited75–100%
- Research Instruments Limited75–100%
- Origio Limitedthis company
Bands show the share of ownership each company holds in the one below it.
From the Persons with Significant Control register (corporate controllers only).
Similar profitable businesses
- Charles River U.K. LimitedKent · Research and experimental development on biotechnology
- Revenue
- £22.2m
- Profit
- £18.8m
- Staff
- 129
- Enara Bio LimitedOxford · Research and experimental development on biotechnology
- Revenue
- £17.4m
- Profit
- £1.3m
- Staff
- 54
- Sitryx Therapeutics LimitedOxford · Research and experimental development on biotechnology
- Revenue
- £23.3m
- Profit
- £4.7m
- Staff
- —
- Theradex (Europe) LimitedRedhill · Research and experimental development on biotechnology
- Revenue
- £15.2m
- Profit
- £3.1m
- Staff
- 43
- Alchemab Therapeutics LtdLondon · Research and experimental development on biotechnology
- Revenue
- £30m
- Profit
- £8.3m
- Staff
- 55
- Dna Legal LimitedFrome · Research and experimental development on biotechnology
- Revenue
- £12.5m
- Profit
- £3.2m
- Staff
- 55
Sources
Latest figures from FullAccounts for the year to 31 Oct 2025 (profit £499k), from the Companies House accounts bulk data published Jul 2026. Spotted an error? Request a correction.
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.